Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma

Схожие документы

• Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
  по: Robert O. Dillman, et al.
  Опубликовано: (2018-03-01)
• Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
  по: Dillman, Robert O., et al.
  Опубликовано: (2018)
• Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines
  по: Dillman, Robert O, et al.
  Опубликовано: (2015)
• Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment
  по: Dillman, Robert O., et al.
  Опубликовано: (2015)
• High-Dose IL2 in Metastatic Melanoma: Better Survival in Patients Immunized with Antigens from Autologous Tumor Cell Lines
  по: Dillman, Robert O., et al.
  Опубликовано: (2014)